Renhaim Therapeutics Inc.

What Renhaim Therapeutics Inc. does

Renhaim Therapeutics Inc. (레나임) is a South Korean pre-commercial biotechnology company founded in December 2021 as a spin-off from Eyegene Co., Ltd. The company develops mRNA-based therapeutics targeting oncology, degenerative disease, and hematological malignancies. Its pipeline addresses three primary patient populations: cancer patients with immune-compromised conditions via mRNA-based cancer vaccines, osteoarthritis patients lacking disease-modifying treatment options via a DMOAD protein replacement therapy, and lymphoma patients via a BAFFR CAR-T cell therapy licensed from PeproMene Bio. The company is headquartered in Uiwang-si, Gyeonggi-do, with a separate R&D center in the same city and a historical shareholder meeting location in Seoul.

The core of Renhaim's offering is an integrated mRNA platform combining mRNA synthesis capability (lab scale through GMP) with a proprietary Lipoplex delivery system using cationic liposomes to protect and intracellularly deliver therapeutic mRNA. The company pairs this delivery and synthesis infrastructure with bioinformatics and AI-based tools to select tumor neoantigens from patient cancer-tissue genetic information. The pipeline is organized across three categories: (i) mRNA cancer vaccines including universal shared-neoantigen, personalized neoantigen, and personalized idiotype (RTX-V002) approaches; (ii) osteoarthritis DMOAD using mRNA-based protein replacement; and (iii) BAFFR CAR-T cell therapy in-licensed from PeproMene Bio with exclusive Korean development and commercialization rights.

Renhaim operates a pre-commercial licensing and co-development business model with no disclosed product revenue. Its go-to-market consists of R&D partnerships with academic institutions, biotech firms, and pharmaceutical companies, complemented by thought-leadership content (e.g., CEO articles in THEBIO) and conference participation including AusBiotech, GBIF, and the National Cancer Center Cancer Science Forum. Key partners include Eyegene (founding parent and licensor of the mRNA Delivery Platform EG-R), PeproMene Bio (BAFFR CAR-T licensor and source of Scientific Advisor Dr. Larry Kwak), Geninus (neoantigen screening for the pancreatic cancer vaccine), ARONTIER (AI-based mRNA design), Seoul National University College of Medicine, and City of Hope (Phase I clinical trial of the personalized LPL vaccine). The company has not publicly disclosed pricing and holds Korean venture company certification (November 2022).

Name

Renhaim Therapeutics Inc.

Legal name

Renhaim Inc.

Website

https://renhaim.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Renhaim Therapeutics is a South Korean pre-commercial biotech developing mRNA-based therapeutics including cancer vaccines, an osteoarthritis DMOAD, and a BAFFR CAR-T cell therapy. The company uses an integrated mRNA synthesis and Lipoplex delivery platform with AI-driven neoantigen selection, targeting licensing and co-development partnerships.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / mRNA Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

Keywords

• MRNA therapeutics
• Cancer vaccines
• Biotech platform
• Lipid nanoparticle delivery
• Cell therapy

Headquarters

HQ city

Uiwang-si

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Pre-commercial / Pipeline Development: As a development-stage biotech company, Renhaim does not yet have commercial revenue. The company is developing multiple therapeutic candidates including cancer vaccines, osteoarthritis treatment, and cell therapy through the clinical development stage.
2. Licensing and Co-development: The company pursues licensing deals and co-development partnerships for its mRNA platform and pipeline candidates. BAFFR CAR-T in-licensing from PeproMene Bio with plans for Korean clinical development and NDA submission.

Go-to-market motion2 records

Marketing channels5 records

Core offering

Renhaim Therapeutics develops mRNA-based therapeutics built on a proprietary mRNA platform that pairs synthetic mRNA production with a Lipoplex nanoparticle delivery system. Its pipeline includes universal and personalized (neoantigen and idiotype) cancer vaccines, a disease-modifying osteoarthritis drug, and a BAFFR-targeted CAR-T cell therapy (RTX-V002) licensed from PeproMene Bio. The company is pre-commercial and targets partners and collaborators for out-licensing and clinical co-development.

Differentiator

Problem solved

Functional benefit

Products and services

• Universal mRNA cancer vaccine Off-the-shelf mRNA-based therapeutic cancer vaccine built on Renhaim's proprietary mRNA platform and Lipoplex delivery system, designed for broad oncology applications.
• Personalized neoantigen mRNA cancer vaccine Patient-specific mRNA cancer vaccine targeting tumor neoantigens identified via Renhaim's AI-based neoantigen selection capability and delivered using the proprietary Lipoplex system.
• Personalized idiotype mRNA cancer vaccine Personalized mRNA vaccine encoding patient-specific idiotypic sequences, built on Renhaim's mRNA platform and Lipoplex delivery technology for hematologic and solid tumor applications.
• Osteoarthritis disease-modifying drug (DMOAD) mRNA-based therapeutic candidate aimed at modifying disease progression in osteoarthritis, leveraging Renhaim's synthetic mRNA and Lipoplex delivery capabilities outside the oncology space.
• RTX-V002 (BAFFR CAR-T cell therapy) BAFFR-targeted CAR-T cell therapy in-licensed from PeproMene Bio, expanding Renhaim's oncology pipeline beyond mRNA into autologous cell therapy.

Quantifiable outcome

• Phase 1 clinical trial showed safety and efficacy of personalized vaccine for lymphoplasmacytic lymphoma with promising immune responses observed in 9 patients

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• City of HopecoreStrategic or Co-development Partner · 27 September 2024Research collaboration through Dr. Larry Kwak who serves as both VP at City of Hope and Scientific Advisor to Renhaim. Phase 1 clinical trial for personalized vaccine conducted at City of Hope. Collaboration aims to advance innovative cancer therapies using Renhaim's mRNA technology.
• PeproMene Bio, Inc.coreStrategic or Co-development Partner · 7 June 2023Strategic partnership for gene and cell therapy development. Renhaim in-licensed BAFFR CAR-T with exclusive rights to develop, manufacture, and commercialize in Korea. Also enlisted Dr. Larry Kwak (PeproMene's core technology developer) to Scientific Advisory Board.
• Genemedicine Co., Ltd.minorStrategic or Co-development Partner · 1 March 2023MOU signed in March 2023 for potential collaboration.
• Geninus Inc. (지니너스)coreStrategic or Co-development Partner · 24 March 2022MOU signed for mRNA-based pancreatic cancer vaccine development. Leveraging Geninus's proprietary Neoantigen Screening technology for antigen candidate identification. Joint R&D agreement signed in August 2022.
• Eyegene Co., Ltd.coreTechnology or Integration · 1 December 2021Founding parent company and technology provider. Eyegene spun off Renhaim Inc. in December 2021. Renhaim licensed in the mRNA Delivery Platform 'EG-R' from Eyegene in February 2022. Also provided bridge investment through BMI Korea.
• Seoul National University College of MedicinecoreStrategic or Co-development PartnerAcademic partnership for research collaboration in mRNA-based drug development.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Gennao Bio: Developer of a non-viral delivery system (GMAB) for nucleic acid therapeutics. Comparable as an emerging player working on novel delivery for nucleic acid payloads, intersecting with Renhaim's Lipoplex focus.
• eTheRNA immunotherapies: Clinical-stage mRNA immunotherapy company developing TriMix-based cancer vaccines and infectious disease vaccines. Comparable as an emerging cancer-vaccine-focused mRNA platform peer.

Direct peers

• CureVac: Clinical-stage mRNA company developing cancer vaccines and protein-encoding therapeutics. Comparable platform player with similar therapeutic ambition but broader resource base.
• PeproMene Bio: Developer of BAFFR-CAR T cell therapy, which Renhaim in-licensed for Korea. Direct therapeutic overlap and a strategic partner/licensor to Renhaim.
• BioNTech: Pioneer in mRNA cancer vaccines with multiple FixVac and individualized neoantigen programs in the clinic. Closest direct peer in modality, target indication, and platform approach.
• Moderna: Global leader in mRNA therapeutics and vaccines with active personalized neoantigen cancer vaccine programs (e.g., mRNA-4157). Directly comparable as an mRNA-platform oncology company, though at vastly greater scale.
• Arcturus Therapeutics: mRNA therapeutics developer with proprietary LNP and delivery technology and oncology programs. Comparable as an mRNA platform peer focused on vaccines and rare diseases.

Broad incumbents

• Sanofi (Translate Bio): Acquired Translate Bio to build an mRNA therapeutics platform across vaccines and oncology. Comparable as a broad incumbent that has vertically integrated mRNA capability, though at vastly greater scale.
• Eyegene: Founding parent and licensor of Renhaim's Lipoplex delivery platform. Comparable as a Korean nucleic-acid therapeutics company, but operating more broadly across gene-based drugs.

Regional players

• KYM Biosciences: South Korean biotech focused on mRNA-based cancer therapeutics. Comparable as a regional peer competing in the same Korean mRNA cancer vaccine niche.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/renhaim_tx
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/renhaim
• Instagraminstagram.com/renhaim.official

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Renhaim Therapeutics Inc.